Long-term follow-up of people with several blood and lymph cancers in Germany
Follows adults with chronic lymphocytic leukemia and related blood cancers over time.
Plain-language title generated from the registry record
Registry title: Registry of the German CLL Study Group
Key facts
- Where
- Dresden, GermanySee the site
Where in Germany
- BAG Freiberg-Richter, Jacobasch, Wolf, IllmerDresden, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- German CLL Study Group
- Trial code
- NCT02863692
- Record updated
- 8 December 2025
- Original description
Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T/Natural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformationRead full original descriptionShow less
Registry of the German CLL Study Group Long Term Follow-up of Patients With CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation
Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T/Natural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation
Inclusion: Confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK-LGL, HCL or Richter's transformation; 18 years of age or older; Signed, written informed consent; Presence of one or more of the following disease situations:; Newly diagnosed patients without treatment indication (eligible for watch and wait Approach Treatment within a clinical trial according to the AMG or status post participation in a clinical Trial); Treatment with standard therapies approved for the eligible entities or status post treatment (outside of clinical trials); Referral for evaluation the indication for HSCT; Relapsed disease status (even if first diagnosis was prior to activation of the registry).
Exclusion: Patients without confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK- LGL, HCL or Richter's transformation; Cerebral dysfunction, legal incapacity.